Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Itacitinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer
- 09 Nov 2021 Status changed from active, no longer recruiting to discontinued.
- 14 Sep 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Oct 2021.